Trials

CELEBRATE

A Phase 2B prospective, blinded, randomized, placebo controlled, international multicenter study to assess restoration of coronary artery blood flow and resolution of ST segment deviation after a single subcutaneous injection of RUC-4 in subjects with ST-elevation myocardial infarction presenting in the ambulance (pre-hospital setting).

This multi-center study designed to enroll 1668 subjects will be conducted at up to 15 clinical sites (hospitals/ambulance services) in the Netherlands and Czech Republic.

CEL-02

A Phase 2A open label study to assess the pharmacodynamic and pharmacokinetic properties of a single subcutaneous injection of RUC-4 in patients with a ST-elevation myocardial infarction presenting to the cardiac catheterization lab with planned primary coronary angioplasty.

This single-center study designed to enroll 24 evaluable subjects will be conducted at the St. Antonius hospital (Nieuwegein, The Netherlands).